Current issues regarding the use of drotrecogin alfa (activated)

Pharmacotherapy

Volumn 22, Issue 12 II, 2002, Pages

  Hassan, Erkan ^a,c   Mann, Henry J ^b  

^a VISICU   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BIOCHEMICAL MARKER; D DIMER; DROTRECOGIN; INTERLEUKIN 6;

ABDOMINAL BLEEDING; BLEEDING; BLOOD CLOTTING; BODY WEIGHT; BRAIN HEMORRHAGE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DOSE CALCULATION; DRUG APPROVAL; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG INFORMATION; DRUG INFUSION; DRUG USE; GASTROINTESTINAL HEMORRHAGE; GENITAL BLEEDING; HEMATURIA; HOSPITALIZATION; HUMAN; INTENSIVE CARE; LONG TERM CARE; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PATIENT MONITORING; PATIENT SELECTION; PRESCRIPTION; RETROPERITONEAL HEMORRHAGE; REVIEW; SEPSIS; SHORT COURSE THERAPY; SKIN BLEEDING; STANDARD; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0036895809     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.18.206s.33707     Document Type: Review

References (16)

1. Bernard GR, Vincent JL, Laterre PF, et al, for the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
2. U.S. Food and Drug Administration. Briefing Document for Xigris for the Treatment of Severe Sepsis. Anti-Infective Drugs Advisory Committee meetings page. Available from www.fda.gov/ohrms/dockets/ac/01/briefing/3797b1_02_ fdabriefing.doc. Accessed September 12, 2001.
3. Esmon CT, Fukudome K, Mather T, et al. Inflammation, sepsis and coagulation. Haematologica 1999;84:254-9.
4. Task Force of the American College of Critical Care Medicine. Guidelines for intensive care unit admission, discharge and triage. Crit Care Med 1999;27:633-8.
5. Ely EW, Bernard GR, Vincent JL. Activated protein C for severe sepsis [letter]. N Engl J Med 2002;347:1035-6.
6. Levine MN, Raskob G, Landefeld S, Hirsh J. Hemorrhagic complications of anticoagulant treatment. Chest 1995;108(suppl):S276-90.
7. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: Clinical epidemiology, prediction and prevention. Am J Med 1993;95:315-28.
8. Society of Critical Care Medicine and American Society of Health-System Pharmacists. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Am J Health-Syst Pharm 2002;59:150-78.
9. Kuhl DA. Current strategies for managing the patient with sepsis. Am J Health-Syst Pharm 2002;59(suppl 1):S9-13.
10. Rivers EM, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77.
11. Fish DN. Optimal antimicrobial therapy in sepsis. Am J Health-Syst Pharm 2002;59(suppl 1):S13-19.
12. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. Practice parameters for hemodynamic support of sepsis in adult patients with sepsis. Crit Care Med 1999;27:639-60.
13. Woods KL, Ketley D. Thrombolysis and acute myocardial infarction. Lancet 1994;343:232-3.
14. Mourouga P, Goldfrad C, Rowan KM. Does it fit? Is it good? Assessment of scoring systems. Curr Opin Crit Care 2000;6:176-83.
15. Livingston BM, MacKirdy FN, Howie JC, Jones R, Norrie JD. Assessment of the performance of five intensive care scoring models within a large Scottish database. Crit Care Med 2000;28:1820-7.
16. Graf J, Doig GS, Cook DJ, Vincent JL, Sibbald WJ. Randomized, controlled clinical trials in sepsis: Has methodological quality improved over time? Crit Care Med 2002;30:461-72.